X

Ongoing Projects

The active research projects are available for viewing on the clinique ovo website, in the waiting room’s television screens and on the clinicaltrials.gov website.

You are free to communicate with the research team for any questions regarding the project that might be of interest to you.

  • Académie

  • Request for information (Accueil)

  • Discover the ovo clinic

  • Contact us

    Contact us

    clinique ovo montreal

    All services offered
    8000, boul. Décarie,
    Montreal Qc H4P 2S4

    ovo fertility
    office 100 & 200
    Monday to Friday 7:30am to 6:00pm
    Weekend on appointment
    fertilite@cliniqueovo.com
    ovo elle
    bureau 600
    Monday to Friday 8:00am to 4:00pm
    elle@cliniqueovo.com
    ovo cryo
    Monday to Wed. 8:00am to 5:00pm
    Thursday 8:00am to 6:00pm
    Friday 8:00am to 5:00pm
    Saturday 9:00am to 3:00pm
    Appointments :
    Monday to Friday 9:00am to 3:00pm
    Thursday 9:00am to 4:00pm
    Saturday 9:00am to 2:30pm
    cryo@cliniqueovo.com
    ovo biosurance
    office 600
    Monday to Friday 8:00am to 4:00pm
    biosurance@cliniqueovo.com
    ovo labo
    office 600
    Monday to Friday 8:00am to 4:00pm
    labo@cliniqueovo.com
    ovo prenatal
    office 600
    Monday to Friday 8:00am to 4:00pm
    prenatal@cliniqueovo.com
    ovo r&d
    office 600
    Monday to Friday 7:15am to 5:00pm
    r-d@cliniqueovo.com

    clinique ovo rive-sud

    3141, boul. Taschereau,
    Greenfield Park Qc J4V 2H2

    ovo fertility – certain services offered
    office 410
    Call to know our hours
    fertilite@cliniqueovo.com
    ovo prenatal – certain services offered
    office 420
    Monday to Friday 8:00am to 4:00pm
    prenatal@cliniqueovo.com
    ovo labo – certain services offered
    office 420
    Monday to Friday 8:00am to 4:00pm
    labo@cliniqueovo.com

    clinique ovo quebec

    ovo prenatal – certain services offered
    2600 Boul. Laurier, suite 295,
    Quebec Qc G1V 4T3

    Monday to Friday 8:00am to 4:00pm
    prenatal@cliniqueovo.com



    clinique ovo rive-nord

    ovo prenatal – Prenatal screening
    1000 Montée des Pionniers,
    Terrebonne QC J6V 1S8

    Monday to Thursday 9:00am to 3:00pm
    prenatal@cliniqueovo.com

    clinique Echo-medic

    Ovo prenatal – certain services

    Laval
    1575, boul. de l’Avenir, suite 110,
    Laval Qc H7S 2N5
    t. 1.877.664.3246
    Monday to Thursday 7:30am to 4:30pm
    Friday 7:30am to 3:00pm
    Boisbriand
    20865, chemin de la Côte Nord, suite 201
    Boisbriand Qc J7E 4H5
    t. 1.877.664.3246
    Monday to Thursday 8:00am to 4:00pm
    Friday 8:00am to 3:00pm
    Montreal and South-Shore: t. 514.798.2000
    Quebec: t. 418.425.0128
    f. 514.798.2001
  • Make an appointment

IN VITRO FERTILIZATION

G-CSF INJECTION
Effects of exogenous recombinant G-CSF results in IVF/ICSI in women with repetitive embryo implantation failure

Principal Investigator: Dr Pierre Lehmann

 

Principal Co-Investigator : Dr Jacques Kadoch

 

Fellow in charge : Dr Chloé Roumain

 

Sponsor: ovo fertility

 

Pharmaceutical Funding: Merck

 

Summary: Recently, scientists have been interested in the G-CSF (Granulocyte – Colony Stimulating Factor) and its used has been increased in reproduction pathologies. The G-CSF, central pivot, would act concomitantly on the ovocyte quality and endometrial receptivity by improving:
> Immunologic tolerance
> Self restoration of chromosome abnormalities in the ovocytes
> Bonding of the embryo to the lining
The purpose of this study is to evaluate the impact of an intra-uterine injection of recombinant G-CSF on pregnancy and implantation rates, during a cycle of IVF-ICSI or during a frozen embryo transfer. This study is intended to women having had 3 or more failed embryo implantation. A repetitive embryo implantation failure is the inability of getting pregnant after 2 to 6 IVF cycles.

 

Number of participants : 290 participants, recruitment will be done only at the clinique ovo.

 

Project coordinator : Nelly Delouya – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 759 or at R-D@cliniqueovo.com.

 

ClinicalTrials.gov ID : NCT02149277

GROWTH HORMONE
Adjuvant growth hormone therapy in in-vitro fertilization: a randomized controlled trial

Principal Investigator : Dr Jacques Kadoch

 

Sponsor : ovo fertility

 

Partnership : EMD Serono Canada

 

Summary: In an In Vitro Fertilization (IVF) cycle, ovarian stimulation drugs (gonadotrophins) are usually taken to stimulate the ovaries to produce more than one egg. IVF protocols are constantly under review in order to improve the recruitment of the follicles, which contains the eggs, while minimizing the doses of gonadotropins required with the ultimate aim of increasing the live birth rate. The addition of growth hormone, which is a biological hormone that can be synthetically produced, as a supplement to gonadotrophins in an IVF cycle, has been suggested as a way in which IVF pregnancy rates may be increased.
The purpose of this study is to determine the effectiveness of using growth hormone therapy as a supplement during her treatment

 

Number of participants : 528, recruitment will be done only at the clinique ovo.

 

Project Coordinator: Michelle Roberge – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 755 or at R-D@cliniqueovo.com.

 

ClinicalTrials.gov ID : NCT01715324

G-CSF FIV Nat
Impact of follicular and blood G-CSF on pregnancy and implantation rate during modified natural in vitro fertility cycle.

Principal Investigator: Dr Pierre Lehmann

 

Principal Co-investigator : Dr. Jacques Kadoch

 

Sponsor : ovo fertility

 

Summary : Recently, scientists have been interested in the G-CSF (Granulocyte – Colony Stimulating Factor) and its used has been increased in reproduction pathologies. Thus, elevated levels of blood and follicular G-CSF the day of the oocyte retrieval would be linked to better implantation and pregnancy rates. The G-CSF, central pivot, would act concomitantly on the ovocyte quality and endometrial receptivity by improving:
> Immunologic tolerance
> Self restoration of chromosome abnormalities in the ovocytes
> Bonding of the embryo to the lining
The purpose of this study is to confirm that the blood and follicular levels of G-CSF are an index of ovocyte quality

 

Number of participants : 224, recruitment will be done only at the clinique ovo.

 

For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 602 or at R-D@cliniqueovo.com.

 

ClinicalTrials.gov ID : NCT01668225

GAVI
Evaluation of an automated vitrification system in comparison with the traditional manual vitrification technique by verifying the impact of the user on the survival rate and on the pregnancy rate.

Principal Investigator: Simon Phillips, Msc, director of the embryology department at clinique ovo.

 

Sponsor: ovo fertility

 

In collaboration with EMD Serono

 

Summary : GAVI, the automated vitrification system (freezing of the embryos) developped by an Australian team and commercialized in Canada since 2016, is being studied to confirm its equivalence with the manual vitrification technique done by the embryologists. Results from previous studies have shown that GAVI’s automated vitrification system is comparable to the CRYOTOP manual technique used at clinique ovo. With this research project, clinique ovo wants to verify if there is an added advantage to using GAVI’s automated vitrification system. Since this system is automated, we believe it may better the results for the cryopreservation (freezing) of embryos.

 

Number of participants needed: 168

 

Number of recruiting sites: 01, clinique ovo

 

Project Coordinator: Lindsay Joseph – To learn more about this research project, please contact (514) 798-2000 ext. 756 or at
R-D@cliniqueovo.com.

CHRONIC ENDOMETRITIS
Chronic endometritis in patients with repetitive miscarriages or repeated implantation failures following IVF treatments.

Principal Investigator : Dr. Joanne Benoît, MD

 

Sponsor : ovo fertility

 

Summary : Chronic endometritis is a persistent inflammation of the endometrium. Clinically, it presents a few or no symptoms. It is sometimes characterized by vaginal bleeding, chronic pelvic pain, discomfort during intercourse and persistent white vaginal discharge. Absence or presence of chronic endometritis is detected by histological analysis of the endometrial biopsy.
Few studies have demonstrated that endometritis may have an impact on the uterine implantation of the embryo and hence, explain repetitive miscarriages and repeated implantation failures.
The aim of this study is to evaluate the frequency of chronic endometritis in patients presenting repetitive miscarriages and repeated implantation failures during in vitro fertilization treatments.

 

Number of participants: 200 women

 

Project Coordinator : Sophie Leblanc – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 617 or at R-D@cliniqueovo.com.

 

INSEMINATION

IUI scratching

 

FIBROME

Asteroid 5 (on break)
A randomized, parallel-group, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids.

test-web-ENG

ENDOMETRIOSIS

Myovant /Spirit 1
A study that aims to evaluate the efficacy and the safety of a new experimental drug called relugolix in the treatment of endometriosis associated pain.

Principal Investigator : Dr. Roland Antaki, MD

 

Sponsor: Myovant

 

Description : To be eligible, participants must have a diagnosis of moderate to severe endometriosis by surgery over the past 10 years. Your participation in this study will last approximately 7-8 months.

 

Project Coordinator: Sophie Leblanc – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 617 or at R-D@cliniqueovo.com.

 

 

STEM CELLS

None.

PRENATAL SCREENING

None.

 

 

MEN’S HEALTH

None.

 

 

DIVERS

MOM
A randomised double blind placebo controlled study evaluating the effect of probiotics for an ongoing healthy pregnancy and the newborn.

Principal Investigator: Dr. Jacques Kadoch

 

Sponsor: Lallemand Health Solutions

 

Summary : During pregnancy, the women’s body experiences many biologic and physiologic changes. Modifications are also observed within the vaginal and intestinal microbiotas. Unbalanced microbiotas may increase risks of pregnancy complications affecting the mother or new born due to some related infections. The current available treatments for these types of urogenital infections may not always work to prevent recurring infections and often they tend to be recurrent, develop resistance and may have some secondary effects and counter-indications.
Many researches have demonstrated the advantages to intake probiotics for the modulation of the immune response. The probiotics contribute in the maintenance of healthy microbiotas by strengthening the inflammatory and immune response as well as the maintenance of a balanced PH level.
Other studies are essential to observe the potential positive effects on pregnant women. The intake of probiotics could benefit the health of pregnant women by reducing the numbers of viral infections and digestive/intestinal troubles. The intake of probiotic during pregnancy and breastfeeding could also demonstrate positive effects on the mother and newborn. This could lower the risk of mastitis, maintain the healthy digestive system development, protecting against the pathogenic agent and regulating the immune response.
The objective of this study is to evaluate the effects of the intake of probiotics during pregnancy and the first few weeks after birth. This objective will be evaluated with the documentation of the number of viral, fungal and bacterial infections, maintenance of a healthy pregnancy and the beneficial impact in pregnant women, their newborn and during breastfeeding.
Number of participants required: 240 pregnant women between 26 and 28 week of pregnancy and being followed by an obstetrician at clinique ovo.

 

Project coordinator : Michelle Roberge

 

For more information on this research project, you may communicate with the project coordinators at 514-798-2000 extension 755 or by email at : R-D@cliniqueovo.com